Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Model of mechanosensation through primary cilia

Published byIndra Pranata Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1 Model of mechanosensation through primary cilia"— Presentation transcript:

1 Figure 1 Model of mechanosensation through primary cilia
Figure 1 | Model of mechanosensation through primary cilia. a | Bending of primary cilia by fluid flow results in a cytosolic Ca2+ signal. Delling et al. now report that this Ca2+ signal is not initiated in the primary cilium (dotted line)7. b | The activation mechanism of the polycystin complex (PC1, TRPP2) and its Ca2+-dependent downstream effectors remain elusive. ER, endoplasmic reticulum. Hofherr , A. & Köttgen, M. (2016) Cilia and mechanosensation revisited Nat. Rev. Nephrol. doi: /nrneph

Download ppt "Figure 1 Model of mechanosensation through primary cilia"

Similar presentations

Mechanosensitive properties in endothelium and their roles in regulation of endothelial function Zhi-Ren Zhang M.D., Ph.D. Harbin Medical University.

Mechanosensitive properties in endothelium and their roles in regulation of endothelial function Zhi-Ren Zhang M.D., Ph.D. Harbin Medical University.
Figure 6 Cholesterol metabolism in obesity-related glomerulopathy

Figure 6 Cholesterol metabolism in obesity-related glomerulopathy
Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.
Figure 2 Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis Figure 2 | Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis.

Figure 2 Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis Figure 2 | Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis.
Figure 6 Effects of adiponectin on podocyte function

Figure 6 Effects of adiponectin on podocyte function
Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.
Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.
Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Expression of coagulation protease receptors in renal cells
Figure 4 Interactions between adipose, the microbiome and kidney

Figure 4 Interactions between adipose, the microbiome and kidney
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 1 Mechanisms of kidney injury in the setting of obesity
Figure 2 Physiological changes in the renal system in pregnancy

Figure 2 Physiological changes in the renal system in pregnancy
Figure 2 Proinflammatory mechanisms in CKD

Figure 2 Proinflammatory mechanisms in CKD
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Pathogenic mechanisms and pathways in ADPKD

Figure 1 Pathogenic mechanisms and pathways in ADPKD
Figure 1 Pathways of complement activation

Figure 1 Pathways of complement activation
Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.
Figure 7 The efficacy of phosphate-binder therapy

Figure 7 The efficacy of phosphate-binder therapy
Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Similar presentations

Ads by Google